🇺🇸 FDA

Company profile · Sponsor

Camurus

Camurus AB

E260AAD · EMA pharma EU
Pipeline
3
Drugs
0
Patents
0

Quick answer

Camurus (E260AAD) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 3 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E260AAD
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (3)

Search pipeline →

  1. CAM2029 (octreotide subcutaneous depot), CAM2029 (octreotide subcutaneous depot)

    Camurus

    Acromegaly

    phase 3 small molecule active

    1 trial

  2. CAM2029 (octreotide subcutaneous depot), SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection, Somatuline Autogel 120 mg, solution for injection in a pre-filled syringe

    Camurus

    gastroenteropancreatic neuroendocrine tumors

    phase 3 small molecule active

    1 trial

  3. A Phase 1 Trial Assessing Pharmacokinetics and Safety of CAM2056 (Semaglutide Subcutaneous Depot)

    Camurus

    Body weight management

    phase 1 other active

    1 trial

Frequently asked questions

What is Camurus?

Camurus (E260AAD) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 3 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Camurus sponsor?

We track 3 ClinicalTrials.gov-linked programs for Camurus, including CAM2029 (octreotide subcutaneous depot), CAM2029 (octreotide subcutaneous depot) and 2 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Camurus company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.